A 2 part phase II trial to evaluate ZD1839 [gefitinib; Iressa] and radiotherapy in patients w/locally [with locally] advanced inoperable squamous cell carcinoma of the head and neck
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 26 Jan 2011
At a glance
- Drugs Gefitinib (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- 26 Jan 2011 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 10 Jan 2007 Status change
- 13 Nov 2005 New trial record.